Mounjaro for diabetes or weight loss: two licences, one pen

The biggest misconception: that there are two different medicines

A question our prescribers hear regularly is whether the Mounjaro pen prescribed for diabetes is somehow different from the one prescribed for weight loss. It is not. The same tirzepatide molecule, the same KwikPen, the same six UK strengths (2.5 mg through to 15 mg), what differs is the clinical indication recorded on your prescription and the criteria your prescriber uses to assess suitability.

That distinction matters more than it sounds. Under the weight-loss licence (MHRA-approved for adults with a BMI of 30 or above, or 27 or above alongside a condition like hypertension or dyslipidaemia), the clinical goal is sustained weight reduction alongside dietary change and increased activity. Under the diabetes licence, the goal is glycaemic control, though meaningful weight loss is frequently a secondary benefit. Both require a proper prescriber assessment, neither is available without one.

The type 2 diabetes indication has been part of the Mounjaro licence since launch. The weight-management indication followed, and it is now the basis on which most private prescriptions are written for people who do not have diabetes.

When you have type 2 diabetes and want to lose weight

This is where the two licences genuinely overlap, and it is also where the clinical conversation becomes most nuanced. Tirzepatide has robust evidence in both settings: the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at the 15 mg dose in adults with obesity but without diabetes over 72 weeks. Separate SURPASS trials demonstrated significant HbA1c reductions in people with type 2 diabetes.

If you have both conditions, a prescriber can legitimately draw on either indication. In practice, they will look at your current diabetes treatment, your HbA1c, your cardiovascular risk and your BMI together. NICE's appraisal of tirzepatide for weight management (TA1026) sets out the eligibility criteria for NHS commissioning, but private prescribers assess the clinical picture as a whole. Keep your pen in the fridge door when you get home, a familiar spot makes the once-weekly routine easier to build, whichever indication applies to you.

Our dedicated page on Mounjaro and type 2 diabetes covers the glycaemic evidence in more detail.

What is not covered: type 1 diabetes, pregnancy and other exclusions

Tirzepatide is not licensed for type 1 diabetes. The mechanism (targeting GIP and GLP-1 receptors to reduce appetite and modulate insulin secretion) is not appropriate for the autoimmune insulin deficiency that defines type 1. People sometimes ask because weight management is also a concern in type 1; a specialist endocrinologist is the right person to discuss those options. Our page on type 1 diabetes and Mounjaro addresses this directly.

Pregnancy, breastfeeding and trying to conceive are all situations where tirzepatide is not recommended, the medicine should be stopped before conception is attempted, and the MHRA advises using effective contraception during treatment. Women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced; NHS England's guidance on weight-management injections covers this clearly.

A personal or family history of medullary thyroid carcinoma or MEN2 syndrome, active pancreatitis, and certain gastrointestinal conditions also require careful prescriber assessment. This is not an exhaustive list, it is why every prescription starts with a proper clinical review.

Getting the right prescription: NHS versus private routes

On the NHS, Mounjaro is being phased in through primary care under NICE TA1026, with criteria tightening around BMI thresholds and qualifying comorbidities. From June 2026, Cohort 2 (BMI 35–39.9 with four or more specific conditions) became eligible, though GP participation remains optional and waiting times vary. If you have type 2 diabetes managed by your GP, the diabetes licence may offer a different NHS access path, discuss this with your GP directly.

For people who do not meet NHS criteria or who prefer not to wait, a regulated private service is the legal alternative. At nume (sorry, at our GPhC-registered pharmacy) a named GPhC-registered Independent Prescriber reads every consultation the same day. They assess whether the weight-loss or diabetes indication applies to your situation, review your health history and confirm clinical suitability before any prescription is written. If you have PCOS alongside weight concerns, there is specific guidance on Mounjaro and PCOS worth reading before your consultation.

You can verify any online pharmacy on the GPhC register before sharing any health information with them. Our registration number is 9012878.